Climb Bio (CLYM) insider buying

Healthcare · Biotechnology · Market cap $580M

3 open-market purchases of CLYM by Climb Bio's executives and directors since December 2025, worth $779,626 in total, from SEC Form 4 filings.

The most recent: Ra Capital Management, L.P. bought $24,888 on January 5, 2026.

The biggest buyer over the period is Ra Capital Management, L.P.: 3 purchases, $779,626.

By year

YearPurchasesValue
20261$24,888
20252$754,737

Biggest buyers

InsiderBuysValue
Ra Capital Management, L.P.
3$779,626

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Jan 5, 2026 Ra Capital Management, L.p.
 7,111$3.50$24,888 Form 4
Dec 12, 2025 Ra Capital Management, L.p.
 101,462$2.86$290,181 Form 4
Dec 11, 2025 Ra Capital Management, L.p.
 213,099$2.18$464,556 Form 4
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLYM.
Open CLYM in Investingly

Questions

Are Climb Bio insiders buying the stock?

3 open-market purchases of CLYM by Climb Bio's executives and directors since December 2025, worth $779,626 in total, from SEC Form 4 filings. The most recent: Ra Capital Management, L.P. bought $24,888 on January 5, 2026.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From Climb Bio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.